Straits Times Index
3,292.23 -0.46 (-0.01%) Nikkei
38,268.37 -5.68 (-0.01%) Hang Seng
18,184.38 +421.35 (+2.37%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,426.73 -2,510.28 (-4.19%) CMC Crypto 200
1,254.54 -84.52 (-6.31%)
Clene Inc. (CLNN)
After hours:
| Previous close | 0.4318 |
| Open | 0.4196 |
| Bid | 0.4351 x 100 |
| Ask | 0.4422 x 100 |
| Day's range | 0.3800 - 0.4389 |
| 52-week range | 0.2500 - 1.0900 |
| Volume | |
| Avg. volume | 957,255 |
| Market cap | 56.126M |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
GlobeNewswireIBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, ho
Simply Wall St.Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
Quite a few insiders have dramatically grown their holdings in Clene Inc. ( NASDAQ:CLNN ) over the past 12 months. An...
GlobeNewswireEvidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8® 30 mg treatment (change from original baseline; p<0.05)Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observedFirst Phase 2 clini
